Namzaric is a fixed-dose combination pill that contains the two active ingredients memantine hydrochloride and donepezil hydrochloride. It belongs to the neurology therapeutic class and is indicated for the treatment of moderate to severe Alzheimer’s disease. The medication is supplied as a 5 mg/5 mg tablet (memantine 5 mg + donepezil 5 mg). In Hong Kong, Namzaric is a prescription-only product regulated by the Department of Health.
Namzaric is approved in Hong Kong for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. The indication is based on regulatory review of clinical trial data that demonstrated improvements in cognition, functional abilities, and global clinical status compared with placebo. The medication is used when monotherapy with either memantine or donepezil alone is insufficient or when a combined strategy is clinically appropriate.
No evidence-based off-label uses for the fixed-dose combination have been identified that meet the required standards for inclusion.
(If future research provides robust data on additional indications, a separate evidence-based review would be warranted.)
These effects are usually transient and may lessen as the body adjusts to the medication.
Any of these symptoms should prompt urgent evaluation.
Patients should provide a complete medication list-including over-the-counter drugs, herbal supplements, and vitamins-to their prescriber.
If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose.
Potential overdose signs include severe nausea, vomiting, diarrhoea, dizziness, and confusion. Immediate medical attention is required; supportive care and gastric lavage may be indicated. No specific antidote exists.
Abrupt cessation is generally safe, but clinicians may recommend a gradual taper for patients who have been on high doses for an extended period to minimise potential rebound symptoms.
Regular follow-up with a neurologist or geriatrician ensures optimal therapeutic benefit and early detection of adverse effects.
This article provides educational information about Namzaric and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Namzaric combines a fixed dose of memantine 5 mg and donepezil 5 mg in one tablet, simplifying the medication regimen. Separate tablets allow flexible dosing adjustments of each component, which may be preferred in patients requiring individualized titration.
Combining multiple acetylcholinesterase inhibitors (e.g., donepezil with rivastigmine) is generally not recommended because it can increase the risk of cholinergic side effects. Any addition should be evaluated by a specialist.
The tablet’s stability is maintained as long as it remains in its original container, tightly sealed, and stored at room temperature. There is no specific “opened” shelf-life separate from the printed expiration date.
Initial titration to a once-daily 5 mg/5 mg dose is standard. After four weeks, clinicians may increase to twice daily if the patient tolerates the therapy and shows insufficient clinical response.
Mild gastrointestinal upset often improves with continued use. If nausea is severe, persistent, or leads to vomiting, contact a healthcare professional for possible dose adjustment or supportive treatment.
No direct pharmacokinetic interaction is known between Namzaric and most antihypertensives. However, clinicians should monitor blood pressure if a patient experiences dizziness or falls, which could be indirectly related.
Namzaric is approved for moderate to severe disease. For mild Alzheimer’s, clinicians typically start with a single-agent therapy, such as donepezil alone, before considering combination treatment.
The tablet can be taken at any consistent time each day. Some patients prefer evening dosing to reduce daytime somnolence, but personal preference and routine are most important.
Pricing varies by pharmacy and insurance coverage in Hong Kong. In some cases, the single-tablet formulation may be more convenient, while separate generics could offer cost flexibility. For exact pricing, consult local pharmacy listings.
